FUJIFILM Cellular Dynamics

What FUJIFILM Cellular Dynamics does

FUJIFILM Cellular Dynamics, Inc. is a Wisconsin-incorporated life sciences company (founded 2004) and wholly-owned subsidiary of FUJIFILM Holdings America Corporation, specializing in human induced pluripotent stem cell (iPSC) technology. The company develops, manufactures, and sells standardized iPSC-derived human cell products under the iCell brand — covering cardiomyocytes, neurons, microglia, astrocytes, hepatocytes, macrophages, endothelial cells, and disease-model variants — for pharmaceutical drug discovery, toxicology and safety pharmacology, disease modeling, and academic research. It also offers GMP iPSC lines, CDMO and cGMP manufacturing services for clinical and commercial cell therapies, custom iPSC generation (MyCell), and extracellular vesicle (EV) solutions. Core intellectual property includes patents on automated cell production and on deriving stem cells from blood, plus the registered iCell trademark.

The company monetizes through one-time licenses for research products, professional services for custom iPSC work, and CDMO contracts for clinical-grade cell manufacturing. Pricing is quote-based across all offerings, with direct sales via the fujifilmcdi.com e-commerce platform and phone channels, supplemented by distribution partners (StemCell Technologies, Seoulin Bioscience in Korea, FUJIFILM Irvine Scientific). Customer segments are horizontal — large pharma (Roche, JCR Pharmaceuticals), biotechnology (BlueRock/Opsis, Cynata, Sana), academia and research institutions, CROs, and adjacent industries such as food and nutrition (Nestle). Marketing relies on industry conferences (BIO, ISSCR, Neuroscience, SLAS), peer-reviewed publications, webinars, and a strong LinkedIn (301,071 followers) and YouTube presence.

FCDI holds the leading 9.24% share of the global iPSC market, which is projected to grow from $1.96B in 2024 to $4.73B in 2034 at a 9.2% CAGR. In May 2026 the company opened a new 175,000-square-foot headquarters and iPSC manufacturing facility in Madison, Wisconsin as part of a $200M strategic investment expected to quadruple research product manufacturing capacity, complemented by the parent-operated $3.2B Holly Springs biomanufacturing facility (800+ employees) and San Diego-based FUJIFILM Biotechnologies California operations. Strategic partnerships with Lonza, Cynata, BlueRock Therapeutics & Opsis Therapeutics, Harvard Stem Cell Institute, Promega, and Sana Biotechnology anchor the company as a platform-level enabler for the broader cell therapy ecosystem.

Name

FUJIFILM Cellular Dynamics

Legal name

FUJIFILM Cellular Dynamics, Inc.

Website

https://fujifilmcdi.com

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

101–250 employees

Short description

FUJIFILM Cellular Dynamics is a wholly-owned subsidiary of FUJIFILM Holdings that manufactures and sells standardized human iPSC-derived cell products (iCell line) and offers CDMO services for cell therapies, serving pharmaceutical, biotechnology, academic, and contract research customers worldwide.

Ownership category

akta.pro rank

Product category

iPSC-Derived Cell Products and Services

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)

Keywords

• Induced pluripotent stem cells
• IPSC-derived cell products
• Cell therapy CDMO services
• GMP iPSC line manufacturing
• Drug discovery cell models

Headquarters

HQ city

Madison

HQ country

United States

HQ region

North America

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

1. Research Products: Sale of human iPSC-derived cells (iCell products) for drug discovery, disease modeling, toxicology screening, and stem cell banking applications. Includes various cell types with associated media and supplements.
2. CDMO Services: Contract development and manufacturing organization services for cell therapy products, including GMP iPSC lines, investigational drug manufacturing, and commercial production capabilities.
3. Custom Services: Custom iPSC generation and differentiation services tailored to specific customer research and therapeutic development needs.
4. CIRM iPSC Products: Products developed under the California Institute for Regenerative Medicine initiative for the research community.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels6 records

Core offering

FUJIFILM Cellular Dynamics develops, manufactures and sells human induced pluripotent stem cell (iPSC)-derived cell products (the iCell family of cardiomyocytes, neural, hepatic, immune and endothelial cells) used by pharmaceutical companies and academic researchers for disease modeling, drug discovery and toxicology screening. The company also offers licensable GMP iPSC lines, CDMO services for cGMP manufacturing of clinical-grade cell therapies, custom iPSC generation and differentiation (MyCell) services, and extracellular vesicle (EV) solutions.

Product overview

FUJIFILM Cellular Dynamics is a life sciences company specializing in human induced pluripotent stem cell (iPSC)-derived products and services. The company operates an integrated portfolio built around its core iCell product family, which includes standardized iPSC-derived cell types (cardiomyocytes, neural cells, hepatocytes, macrophages, endothelial cells) sold as off-the-shelf research products, supplemented by custom differentiation services under the MyCell brand. The product portfolio spans four major cell categories: Cardiovascular Cells (iCell Cardiomyocytes, iCell Cardiomyocytes2, iCell CardioSpheres), Neural Cells (iCell DopaNeurons, iCell GABANeurons, iCell GlutaNeurons, iCell Microglia, iCell Motor Neurons, iCell Astrocytes), and Gut, Liver & Immune Cells (iCell Hepatocytes 2.0, iCell Macrophages 2.0, iCell Endothelial Cells). Disease model variants with patient-specific mutations are available across major therapeutic areas. On the manufacturing side, the company offers GMP iPSC Lines for clinical use and full CDMO Services including contract manufacturing and extracellular vesicle solutions. The portfolio is complemented by specialized media and supplements, custom cell services, and CIRM-funded products.

Differentiator

Problem solved

Functional benefit

Brands

• iCell: Product line of human iPSC-derived cells including cardiomyocytes, neural cells, and hepatocytes

Products and services

• iCell Cardiomyocytes Human iPSC-derived cardiomyocytes sold as an off-the-shelf research reagent for cardiovascular research, drug discovery, and safety pharmacology testing.
• iCell Cardiomyocytes2 Second-generation human iPSC-derived cardiomyocytes with improved functionality sold for cardiac research applications.
• iCell CardioSpheres & CardioSpheres2 Kits Human 3D cardiac microtissues co-cultured from iCell Cardiomyocytes, iCell Endothelial cells and iCell Cardiac Fibroblasts, sold as kits for more physiologically relevant cardiac models.
• iCell DopaNeurons Human iPSC-derived dopaminergic neurons sold as a research reagent for Parkinson's disease research, drug discovery, and cell therapy development.
• iCell GABANeurons Human iPSC-derived GABAergic neurons sold for neuroscience research, disease modeling, and drug discovery applications.
• iCell GlutaNeurons Human iPSC-derived glutamatergic neurons sold as research reagents for neurological disease research and neurotoxicity screening.
• iCell Microglia Human iPSC-derived microglia sold as a research reagent for neuroinflammation research and neurological disease modeling.
• iCell GFP Microglia Green fluorescent protein expressing human iPSC-derived microglia sold for visualization in complex 2D and 3D cell culture protocols.
• iCell Motor Neurons Human iPSC-derived motor neurons sold for ALS research, disease modeling, and drug discovery applications.
• iCell Astrocytes & iCell Astrocytes 2.0 Human iPSC-derived astrocytes (and an enhanced Astrocytes 2.0 variant) sold for neurobiology research, disease modeling, and drug discovery.
• iCell Brain Microvascular Endothelial Cells (BMEC) Kit Human iPSC-derived brain microvascular endothelial cells sold in kit form for blood-brain barrier research and CNS drug delivery studies.
• iCell Blood-Brain Barrier Isogenic Kit Isogenic iPSC-derived blood-brain barrier cell kit sold for comparative studies of barrier function and drug penetration.
• iCell Hepatocytes 2.0 Human iPSC-derived hepatocytes sold as a research reagent for liver disease modeling, drug metabolism, and hepatotoxicity testing.
• iCell Macrophages 2.0 Human iPSC-derived macrophages sold in kit form for immunology research, disease modeling, and drug discovery applications.
• iCell Endothelial Cells Human iPSC-derived endothelial cells sold for vascular research, blood-brain barrier modeling, and tissue engineering.
• Disease Model iPSC Products Off-the-shelf iPSC-derived cell products carrying disease-relevant mutations for research into Alzheimer's disease, Parkinson's disease, ALS, cardiovascular disorders, epilepsy and other conditions.
• Cell Media & Supplements Specialized cell culture media and supplements optimized for maintaining and differentiating iPSC-derived cell products, sold to support iCell research use.
• GMP iPSC Lines Licensable GMP (Good Manufacturing Practice) cell lines sold for clinical and commercial manufacturing of cell therapies.
• CDMO Services Contract development and cGMP manufacturing services for clinical-grade human cells and cell therapy products, including investigational drug product manufacturing and commercial production.
• Custom iPSC Services (MyCell) Custom iPSC generation, differentiation and characterization services tailored to specific customer research and therapeutic development needs.
• Extracellular Vesicles (EV) Solutions Extracellular vesicle isolation and characterization services and products for cell therapy and regenerative medicine applications.
• CIRM iPSC Products California Institute for Regenerative Medicine (CIRM)-funded iPSC products and resources for the research community.

Quantifiable outcome

• 4x increase in iPSC-based research product manufacturing capacity
• +2 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Ten partnerships are on record, tiered core and minor.

• Cynata TherapeuticscoreStrategic or Co-development PartnerStrategic manufacturing agreement for iPSC-derived regenerative medicine products. FUJIFILM Cellular Dynamics to manufacture Cynata's Cymerus iPSC-derived cell therapy products.
• LonzacoreStrategic or Co-development PartnerAgreement to expand the availability and use of induced pluripotent stem cell technology. Combined expertise to serve global research and therapeutic markets.
• RochecoreStrategic or Co-development PartnerCollaboration on drug discovery using human iPSC-derived cells. Deepened engagement in drug discovery applications.
• Harvard Stem Cell InstituteminorStrategic or Co-development PartnerCollaboration agreement for stem cell research and applications. Academic partnership for advancing iPSC technology.
• BlueRock Therapeutics & Opsis TherapeuticscoreStrategic or Co-development PartnerStrategic R&D alliance to discover and develop cell therapies for eye diseases. Focus on retinal cell therapies using iPSC technology.
• Sana BiotechnologyminorOEM/ Whitelabel/ Licensing PartnerLicense agreement for the development of iPSC-derived cell therapies. Sana licenses FUJIFILM Cellular Dynamics technology.
• StemCell TechnologiesminorChannel Partner/ Reseller/ DistributorDistribution agreement to expand product availability in research markets.
• Seoulin BioscienceminorChannel Partner/ Reseller/ DistributorDistribution agreement for FUJIFILM Cellular Dynamics products in Korea.
• Phenovista BiosciencesminorStrategic or Co-development PartnerStrategic alliance to improve the drug discovery process through combined expertise in cell biology and assay development.
• FUJIFILM Irvine ScientificminorChannel Partner/ Reseller/ DistributorDistribution relationship where FUJIFILM Irvine Scientific sells iCell products as part of expanded life sciences portfolio.

Scale indicators8 records

Recent moves8 records

Expansion highlights5 records

Broad incumbents

• Lonza: Global leader in cell and gene therapy CDMO services with massive manufacturing capacity. Also a strategic partner with FCDI for iPSC technology expansion, creating both partnership and direct competitive overlap in iPSC-derived cell manufacturing.
• Catalent: Major CDMO offering cell therapy, gene therapy, and biologics manufacturing services. Comparable as a large-scale contract manufacturer serving similar pharma customers developing advanced therapies.
• Thermo Fisher Scientific: Diversified life sciences tools and CDMO player serving pharma with cell culture media, instruments, and manufacturing services. Overlaps with FCDI through research products and bioproduction offerings.

Direct peers

• Bio-Techne: Supplies cell biology reagents, iPSC-related culture media, and differentiation kits to research and pharma customers. Directly comparable as a supplier of enabling tools for stem cell research and cell therapy development.
• StemCell Technologies: Major supplier of cell culture media, reagents, and primary cells for stem cell research. Both a distribution partner and direct competitor in the iPSC research products market.

Emerging players

• Century Therapeutics: Clinical-stage iPSC-derived cell therapy developer for oncology and autoimmune indications. Comparable as a developer leveraging iPSC technology, though more therapeutic-product focused than FCDI's tools-and-services model.
• Fate Therapeutics: iPSC-derived NK and T-cell therapy developer with proprietary platform. Operates in adjacent iPSC therapeutic space, validating the broader iPSC opportunity FCDI enables as a tools/CDMO provider.
• BlueRock Therapeutics: iPSC-derived cell therapy developer (cardiac, neural, ocular) and strategic partner of FCDI. Comparable as a downstream customer/partner validating FCDI's iPSC platform for clinical-stage programs.
• Cynata Therapeutics: iPSC-derived mesenchymal stem cell therapy developer with manufacturing agreement with FCDI. Comparable as both partner and customer, representing the therapeutic-product category FCDI's CDMO serves.

Others

• Corning Life Sciences: Supplier of cell culture vessels, surfaces, and media supporting iPSC workflows. Comparable as an enabling supplier to the same pharma and academic customers developing cell-based research and therapies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks1 record

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/user/cellulardynamics
• LinkedInlinkedin.com/company/301071
• Xx.com/CellDynamics
• Facebookfacebook.com/FujifilmCDI

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about FUJIFILM Cellular Dynamics